Streetbeat News

Revenues

RBLX

Over the past quarter, 16 analysts have provided diverse opinions on Roblox (NYSE:RBLX), ranging from bullish to bearish. The average 12-month price target for RBLX has been raised to $44.62, reflecting a 26.4% increase from the previous target of $35.30. Analysts from firms like Wedbush, Benchmark, Goldman Sachs, BMO Capital, Wells Fargo, Piper Sandler, JP Morgan, Raymond James, and Needham have maintained or raised their ratings and price targets, indicating a generally positive outlook on the company's performance. Roblox's financials show strong revenue growth and net margin but below-average ROE and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 3:00 pm

RDY

Dr. Reddy's Laboratories reported a year-over-year increase in Q3 2024 earnings per share (EPS) to Rs82.68 from Rs74.95, and a revenue increase to Rs72.148 million from Rs67.700 million.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 2:52 pm

CCG

Cheche Group reported a significant decrease in its adjusted earnings per share (EPS) for Q3, with a loss of RMB(16.16) compared to a loss of RMB(2.59) year-over-year. However, the company's revenue increased to RMB823.3 million from RMB744.862 million in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 2:32 pm

OILFF

Nextleaf Solutions Ltd., a Canadian cannabis company, reported an 85% increase in net revenue for fiscal 2023, reaching CA$8.2 million. The company achieved positive cash flow for four consecutive quarters, reduced operating expenses, and improved gross margins. Gross profit rose to CA$2.31 million from CA$661,238 in 2022, while expenses decreased to CA$2.28 million from CA$4.02 million. The company also reported income of CA$223,334, turning around from a loss of CA$3.48 million in 2022. Nextleaf has retired its senior note, becoming debt-free and strengthening its balance sheet. However, shares of Nextleaf traded slightly lower at $0.0448 per share after the market close on Tuesday.

Portfolio Pulse from Jelena Martinovic

January 31, 2024 | 2:22 pm

INVZ

Innoviz Technologies has announced an operational realignment which includes transitioning its InnovizOne product into series production and reducing its workforce by 13%. The company expects these changes to decrease its planned cash outlays for 2024 by $22M-$24M.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 2:11 pm

ARE

Four analysts have recently updated their ratings on Alexandria Real Estate Equities Inc (NYSE:ARE), with two maintaining a bullish stance and two somewhat bullish. The average 12-month price target is now $143.5, down from $152.50, with a high estimate of $154.00 and a low of $140.00. Analysts from Wedbush, Deutsche Bank, Mizuho, and JMP Securities have provided their latest evaluations and price targets. Alexandria Real Estate, an urban office REIT, has shown strong financial performance with a revenue growth rate of 15.81% as of December 31, 2023, and a net margin of -11.7%. The company's debt-to-equity ratio is 0.63, below the industry average.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 2:00 pm

LVO

LiveOne has announced a partnership with Legible, providing LiveOne members with access to a vast library of music, podcasts, radio stations, and a significant collection of audiobooks and ebooks. The global audiobook market, valued at over $5 billion, is expected to grow to $42 billion by 2031, indicating a substantial market opportunity for LiveOne.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 1:53 pm

GMM

Global Mofy Metaverse (GMM) reported a significant increase in FY23 earnings per share (EPS) to $0.26, up from a loss of $(0.01) in the previous year. Revenue also saw a substantial rise to $26.9 million, up from $17.2 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 1:50 pm

AZN

LLY

NVO

PFE

Eli Lilly (LLY) and Novo Nordisk (NVO) are expected to impress investors with their Q4 earnings, driven by the success of their diabetes treatments, which are also popular for weight loss. Eli Lilly is anticipated to report a 32.1% increase in EPS and a 21.4% rise in revenue. Novo Nordisk already beat earnings and revenue estimates. Despite potential competition from Pfizer (PFE) and AstraZeneca (AZN), the market for weight-loss drugs is expected to grow, with Goldman Sachs predicting a $100 billion market by 2030.

Portfolio Pulse from Neil Dennis

January 31, 2024 | 1:49 pm

ORGS

Orgenesis Inc. has agreed to give Metalmark a 5% royalty on the net revenue of Octomera's cell processing services for the years 2025-2027.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 1:45 pm